Effect of immunization with prostaglandin metabolites on gastrointestinal ulceration.
Active immunization of rabbits with a 6-ketoprostaglandin F1 alpha-thyroglobulin conjugate induced gastrointestinal ulceration, whereas active immunization of rabbits with 13,14-dihydro-15-keto prostaglandin E2-thyroglobulin conjugate or with thyroglobulin alone did not result in ulceration. Passive immunization of a separate group of rabbits with 6-ketoprostaglandin F1 alpha-hyperimmune plasma, obtained from actively 6-ketoprostaglandin F1 alpha-immunized donor rabbits that had ulcers, induced gastric ulceration within 9 days, whereas passive immunization of rabbits with control plasma, obtained from donor rabbits actively immunized with thyroglobulin alone, did not induce ulceration. Ulcerogenic donor plasma containing antibody to 6-ketoprostaglandin F1 alpha neutralized the inhibitory actions of prostacyclin on adenosine diphosphate-induced platelet aggregation, indicating that this antibody cross-reacted with prostacyclin. In contrast, plasma containing antibodies to 13,14-dihydro-15-ketoprostaglandin E2 cross-reacted only slightly with prostaglandin E2. Thus antibodies to inactive metabolites of prostaglandins induce ulceration only if these antibodies cross-react with an endogenous, "cytoprotective" prostaglandin.
Redfern
J S
JS
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas 75235.
Lee
E
E
Feldman
M
M
D015121:6-Ketoprostaglandin F1 alpha / Q000008:administration & dosage* / Q000096:biosynthesis; D000818:Animals; D000917:Antibody Formation; D015232:Dinoprostone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000096:biosynthesis; D005753:Gastric Mucosa / Q000378:metabolism; D007114:Immunization; D007116:Immunization, Passive; D007410:Intestinal Diseases / Q000276:immunology / Q000517:prevention & control*; D007413:Intestinal Mucosa / Q000378:metabolism; D008297:Male; D011817:Rabbits; D013276:Stomach Ulcer / Q000276:immunology / Q000517:prevention & control*; D013954:Thyroglobulin / Q000008:administration & dosage*; D014456:Ulcer / Q000276:immunology / Q000517:prevention & control*
C058052:15-keto-13,14-dihydroprostaglandin E2-thyroglobulin conjugate; C058051:6-ketoprostaglandin F1 alpha-thyroglobulin conjugate; C025087:15-keto-13,14-dihydroprostaglandin E2; D015121:6-Ketoprostaglandin F1 alpha; D013954:Thyroglobulin; D015232:Dinoprostone